Artiva Biotherapeutics, Inc. (ARTV) Revenue History
Annual and quarterly revenue from 2020 to 2024
Compound Annual Growth Rate (CAGR)
Loading revenue history...
ARTV Revenue Growth
ARTV Revenue Analysis (2020–2024)
As of May 8, 2026, Artiva Biotherapeutics, Inc. (ARTV) generated trailing twelve-month (TTM) revenue of $0. The most recent quarter (Q3 2025) recorded $0 in revenue.
Looking at the longer-term picture, ARTV's historical revenue data shows a 3-year CAGR of -50.0%. The company achieved its highest annual revenue of $33.5 million in 2023.
When compared to Healthcare sector peers including FATE (-51.2% YoY), NKTR (-43.9% YoY), and STTK (-78.3% YoY). Compare ARTV vs FATE →
ARTV Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| ARTVCurrent | $0 | - | - | -26805.6% | |
 FATE | $7M | -51.2% | -26.7% | -2222.4% | |
 NKTR | $55M | -43.9% | -18.4% | -236.8% | |
 STTK | $1M | -78.3% | -36.8% | -5150.8% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 CRSP | $4M | -88.9% | +37.3% | -16191.4% |
ARTV Historical Revenue Data (2020–2024)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $251K | -99.3% | $251K | 100.0% | $-67,282,000 | -26805.6% |
| 2023 | $33.5M | +579.2% | $33.5M | 100.0% | $-30,671,000 | -91.6% |
| 2022 | $4.9M | +146.3% | $4.9M | 100.0% | $-59,829,000 | -1213.3% |
| 2021 | $2.0M | - | $2.0M | 100.0% | $-53,272,000 | -2660.9% |
| 2020 | $0 | - | $0 | - | $-18,271,000 | - |
See ARTV's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ARTV Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ARTV vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonARTV — Frequently Asked Questions
Quick answers to the most common questions about buying ARTV stock.
Is ARTV's revenue growth accelerating or slowing?
ARTV TTM revenue: $0.00. YoY growth: N/A. 5-year CAGR: N/A.
What is ARTV's long-term revenue growth rate?
Artiva Biotherapeutics, Inc.'s 5-year revenue CAGR of N/A reflects the variable expansion pattern. Current YoY growth of N/A is near this long-term average.
How is ARTV's revenue distributed by segment?
ARTV reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2020-2024 are available for download. Segment mix reveals concentration and diversification trends.